Literature DB >> 21655434

How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?

Patrick G Telmer1, Cornelia Tolg, James B McCarthy, Eva A Turley.   

Abstract

The mechanisms responsible for the oncogenic effects of the hyaluronan (HA) receptor and mitotic spindle binding protein, RHAMM, are poorly understood. On one hand, extracellular RHAMM interacts with HA and cellsurface receptors such as CD44 to coordinately activate the MAPK/ERK1,2 pathway, thus contributing to the spread and proliferation of tumor cells. On the other hand, intracellular RHAMM decorates mitotic spindles and is necessary for spindle formation and progression through G2/M and overexpression or loss of RHAMM can result in multipole spindles and chromosome missegregation. The deregulation of these intracellular functions could lead to genomic instability and fuel tumor progression. This suggests that both extracellular and intracellular RHAMM can promote tumor progression. Intracellular RHAMM can bind directly to ERK1 to form complexes with ERK2, MEK1 and ERK1,2 substrates, and we present a model whereby RHAMM's function is as a scaffold protein, controlling activation and targeting of ERK1,2 to specific substrates.

Entities:  

Keywords:  CD168; HMMR; MAPK; RHAMM; cancer biology; cell cycle; cell migration; mitosis

Year:  2011        PMID: 21655434      PMCID: PMC3104573          DOI: 10.4161/cib.4.2.14270

Source DB:  PubMed          Journal:  Commun Integr Biol        ISSN: 1942-0889


  22 in total

1.  Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties.

Authors:  A Levchenko; J Bruck; P W Sternberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

Review 2.  Signaling properties of hyaluronan receptors.

Authors:  Eva A Turley; Paul W Noble; Lilly Y W Bourguignon
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

3.  XRHAMM functions in ran-dependent microtubule nucleation and pole formation during anastral spindle assembly.

Authors:  Aaron C Groen; Lisa A Cameron; Margaret Coughlin; David T Miyamoto; Timothy J Mitchison; Ryoma Ohi
Journal:  Curr Biol       Date:  2004-10-26       Impact factor: 10.834

4.  Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.

Authors:  Christopher A Maxwell; Jonathan J Keats; Andrew R Belch; Linda M Pilarski; Tony Reiman
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

5.  The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

Authors:  Vladimir Joukov; Aaron C Groen; Tatyana Prokhorova; Ruth Gerson; Erinn White; Alison Rodriguez; Johannes C Walter; David M Livingston
Journal:  Cell       Date:  2006-11-03       Impact factor: 41.582

6.  Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.

Authors:  M Crainie; A R Belch; M J Mant; L M Pilarski
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

7.  Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

Authors:  Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Anita Schmitt; Dieter Kirchner; Gertraud Krähn; Volker Heilmann; Jürgen Gschwend; Lothar Bergmann; Hartmut Döhner; Michael Schmitt
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

8.  h3/Acidic calponin: an actin-binding protein that controls extracellular signal-regulated kinase 1/2 activity in nonmuscle cells.

Authors:  Sarah Appel; Philip G Allen; Susanne Vetterkind; Jian-Ping Jin; Kathleen G Morgan
Journal:  Mol Biol Cell       Date:  2010-02-24       Impact factor: 4.138

9.  RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.

Authors:  Christopher A Maxwell; Jonathan J Keats; Mary Crainie; Xuejun Sun; Tim Yen; Ellen Shibuya; Michael Hendzel; Gordon Chan; Linda M Pilarski
Journal:  Mol Biol Cell       Date:  2003-03-20       Impact factor: 4.138

10.  Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.

Authors:  K Giannopoulos; A Dmoszynska; M Kowal; J Rolinski; E Gostick; D A Price; J Greiner; M Rojewski; S Stilgenbauer; H Döhner; M Schmitt
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

View more
  21 in total

1.  RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Authors:  Sylvia Snauwaert; Stijn Vanhee; Glenn Goetgeluk; Greet Verstichel; Yasmine Van Caeneghem; Imke Velghe; Jan Philippé; Zwi N Berneman; Jean Plum; Tom Taghon; Georges Leclercq; Kris Thielemans; Tessa Kerre; Bart Vandekerckhove
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

2.  In vitro elucidation of the role of pericellular matrix in metastatic extravasation and invasion of breast carcinoma cells.

Authors:  Marie-Elena Brett; Heather E Bomberger; Geneva R Doak; Matthew A Price; James B McCarthy; David K Wood
Journal:  Integr Biol (Camb)       Date:  2018-04-23       Impact factor: 2.192

3.  Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.

Authors:  Weikun Xiao; Rongyu Zhang; Alireza Sohrabi; Arshia Ehsanipour; Songping Sun; Jesse Liang; Christopher M Walthers; Lisa Ta; David A Nathanson; Stephanie K Seidlits
Journal:  Cancer Res       Date:  2017-12-27       Impact factor: 12.701

4.  HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells.

Authors:  Jessica Tilghman; Hao Wu; Yingying Sang; Xiaohai Shi; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa; Charles G Eberhart; John Laterra; Mingyao Ying
Journal:  Cancer Res       Date:  2014-04-07       Impact factor: 12.701

5.  Expression patterns of CD168 correlate with the stage and grade of squamous cell carcinoma of head and neck.

Authors:  Korinna Jöhrens; Ioannis Anagnostopoulos; Steffen Dommerich; Jan Dirk Raguse; Agnieszka J Szczepek; Frederick Klauschen; Katharina Stölzel
Journal:  Mol Clin Oncol       Date:  2017-02-13

6.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.

Authors:  Zhongyuan Wang; Yanping Wu; Haifeng Wang; Yangqing Zhang; Lin Mei; Xuexun Fang; Xudong Zhang; Fang Zhang; Hongbo Chen; Ying Liu; Yuyang Jiang; Shengnan Sun; Yi Zheng; Na Li; Laiqiang Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

Review 7.  Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy.

Authors:  Annele Sainio; Hannu Järveläinen
Journal:  Mol Cell Ther       Date:  2014-05-02

8.  Identification of novel hub genes associated with gastric cancer using integrated bioinformatics analysis.

Authors:  Xiao-Qing Lu; Jia-Qian Zhang; Sheng-Xiao Zhang; Jun Qiao; Meng-Ting Qiu; Xiang-Rong Liu; Xiao-Xia Chen; Chong Gao; Huan-Hu Zhang
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

Review 9.  Hypotheses on the evolution of hyaluronan: a highly ironic acid.

Authors:  Antonei B Csoka; Robert Stern
Journal:  Glycobiology       Date:  2013-01-12       Impact factor: 4.313

Review 10.  The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression.

Authors:  Dragana Nikitovic; Katerina Kouvidi; Nikos K Karamanos; George N Tzanakakis
Journal:  Biomed Res Int       Date:  2013-09-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.